<p><strong>Diarrhea</strong>: Aggressively manage diarrhea occurring despite recommended prophylaxis with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold Meratinib in patients experiencing severe and/or persistent diarrhea. Permanently discontinue Meratinib in patients experiencing Grade 4 diarrhea or Grade &ge; 2 diarrhea that occurs after maximal dose reduction.<br />
<br />
<strong>Hepatotoxicity</strong>: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold Meratinib in patients experiencing Grade 3 liver abnormalities and permanently discontinue Meratinib in patients experiencing Grade 4 liver abnormalities.<br />
<br />
<strong>Embryo-Fetal Toxicity</strong>: Meratinib can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.</p>